Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT05604261 Not yet recruiting - Clinical trials for Gastroesophageal Reflux

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Start date: December 2022
Phase: Phase 2
Study type: Interventional

A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with Rabeprazole 20mg QD in patients with reflux esophagitis.

NCT ID: NCT05587322 Active, not recruiting - Clinical trials for Non-erosive Reflux Disease

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

Start date: September 6, 2022
Phase: Phase 3
Study type: Interventional

The objective of the Treatment Phase of the study is to evaluate the safety and efficacy of 4 weeks of once daily oral administration of BLI5100 low dose, BLI5100 high dose, or placebo in patients with NERD. The objective of the Extension Phase of the study is to evaluate the safety of extended exposure to once daily oral administration of BLI5100 low dose and BLI5100 high dose in patients with NERD.

NCT ID: NCT05579587 Not yet recruiting - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients

TIF-LPR
Start date: March 30, 2024
Phase:
Study type: Observational

In this research study the investigators want to learn more about the effectiveness of an endoscopic procedure (an endoscope is a lighted tube that is placed down the participants esophagus, through the participants mouth) which uses a device that allows the doctor to repair or recreate the body's natural barrier to reflux. It uses preloaded forceps (tweezers) and fasteners and requires no incision to tighten the connection between the participants esophagus and stomach. This procedure is performed to aid in the treatment of symptoms of Gastroesophageal Reflux disease (GERD) in patients with diagnosed Laryngopharyngeal reflux (LPR). LPR is a condition resulting from backflow of stomach contents into the laryngopharynx (connection point in the participants throat through which food, water, and air pass) resulting in symptoms that can be referred to larynx/hypopharynx. The device the investigators will use to perform the transoral incisionless fundoplication procedure (TIF) is called the EsophyX device. The participants have been asked to participate because they have been diagnosed with LPR and have either failed medical therapy (taking prescription proton pump inhibitors (PPI) to reduce stomach acid production or do not want to be on long-term medical treatment.

NCT ID: NCT05579444 Terminated - Obesity Clinical Trials

Systems Biology of Gastrointestinal and Related Diseases

Start date: November 11, 2022
Phase:
Study type: Observational

This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and remissions, or progression of their disease.

NCT ID: NCT05570448 Recruiting - Clinical trials for Gastro Esophageal Reflux

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

AREA21
Start date: February 15, 2022
Phase: N/A
Study type: Interventional

This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months. Patients must have a positive pH test and a negative manometry (no treatment) procedure.

NCT ID: NCT05561179 Recruiting - Clinical trials for Gastroesophageal Reflux

Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease

Start date: September 30, 2022
Phase: N/A
Study type: Interventional

Gastroesophageal reflux disease (GERD) remains one of the most common pathologies seen among gastroenterologists, surgeons, and primary care physicians. The high prevalence of this condition lead to further investigations in its prevention, diagnosis, and management. For the treatment of this chronic condition, improvement in quality of life and long-term durability should be considered. Nowadays, proton pump inhibitors (PPIs) are considered the mainstay in the treatment of the patients with GERD; however, due to the increasing concern related to its safety in its long-term use and the over prescription of these drugs, new surgical and endoscopic interventions have emerged. A local treatment based on injections of hyaluronic acid, a natural nonimmunogenic mucosal defense, in the lower esophageal mucosa is a tentative treatment option for these patients. Based on this, the investigators pursue to assess the effects of hyaluronic acid in gastroesophageal reflux control.

NCT ID: NCT05556824 Recruiting - Clinical trials for Gastroesophageal Reflux

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

Start date: March 3, 2023
Phase: Phase 2
Study type: Interventional

This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.

NCT ID: NCT05514769 Recruiting - Gastric Cancer Clinical Trials

Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This research is designed to compare proximal gastrectomy anterior anastomosis with pyloroplasty with esophagogastric anastomosis for gastric cancer. Gastroesophageal reflux disease, postoperative quality of life, short term outcomes, and long term outcomes will be compared.

NCT ID: NCT05500196 Recruiting - Gastric Reflux Clinical Trials

Impact of Gastric Length of Myotomy During POEM on Gastroesophageal Reflux

IGL
Start date: July 7, 2021
Phase:
Study type: Observational

This observational study will be conducted among 43 patients of both sexes in each group Study participants will be of the age more than 18 years - STUDY PROCEDURE-Pre-defined technique to avoid bias and confounding due to multiple factors - All the poem procedures will be performed by posterior route - Preservation of sling fibers will be attempted in all the cases to avoid heterogeneity - Length of esophageal myotomy will be kept constant (4-6cm) - Double scope technique will be utilized to confirm the gastric extent of myotomy First evaluation at 1-month: based on Symptoms • Second evaluation: at 6 months by - Objective evaluation: UGI endoscopy, High resolution manometry, Timed barium swallow - Eckardt score, GERD-HRQL - 24-hour pH study with manual readings

NCT ID: NCT05493436 Completed - Clinical trials for Disorder of Upper Esophageal Sphincter

The Influence of Obesity to Esophageal Reflux Severity Measured by pH-Metri Impedans on Gastroesophageal Reflux Disease Patients

Start date: April 1, 2017
Phase:
Study type: Observational

To see a more convincing relationship between increased body mass index and the severity of esophageal reflux in GERD patients, GERD diagnosis should be performed with greater precision or precision. From the available data, it appears that no studies in Indonesia have correlated the body mass index with the severity of esophageal reflux events measured by multical intraluminal intraluminal pH-metric in patients with GERD due to the invasive nature of the test. Therefore, research needs to be done to assess the effect of increased body mass index on the severity of esophageal reflux as measured by multical intraluminal impedance pH-metric in GERD patients.